Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Catalog Number Size Price
LS-C122532-100 100 µg $564 
Antibody

Monoclonal Mouse anti‑Human KDR / VEGFR2 / FLK1 Antibody (Extracellular Domain, IHC, WB) LS‑C122532

Monoclonal Mouse anti‑Human KDR / VEGFR2 / FLK1 Antibody (Extracellular Domain, IHC, WB) LS‑C122532

Antibody:
KDR / VEGFR2 / FLK1 Mouse anti-Human Monoclonal (Extracellular Domain) Antibody
Application:
IHC, IHC-P, IHC-Fr, WB
Reactivity:
Human
Format:
Unconjugated, Unmodified
Price
Catalog Number
$564
LS-C122532-100
Toll Free North America
206-374-1102
For Research Use Only

Overview

Antibody:
KDR / VEGFR2 / FLK1 Mouse anti-Human Monoclonal (Extracellular Domain) Antibody
Application:
IHC, IHC-P, IHC-Fr, WB
Reactivity:
Human
Format:
Unconjugated, Unmodified

Specifications

Description
FLK1 antibody LS-C122532 is an unconjugated mouse monoclonal antibody to human FLK1 (KDR / VEGFR2) (Extracellular Domain). Validated for IHC and WB. Cited in 1 publication.
Target
Human KDR / VEGFR2 / FLK1
Synonyms
KDR | CD309 | Fetal liver kinase 1 | Fetal liver kinase-1 | FLK-1 | FLK1 | Kinase insert domain receptor | Quek1 | VEGFR | VEGFR2 | Soluble VEGFR2 | VEGF receptor 2 | VEGFR-2 | CD309 antigen | VEGF-R2
Host
Mouse
Reactivity
Human (tested or 100% immunogen sequence identity)
Clonality
IgG1 Monoclonal
Conjugations
Unconjugated
Purification
Immunoaffinity purified
Modifications
Unmodified
Immunogen
Recombinant human extracellular domain of VEGFR-2 (KDR).
Epitope
Extracellular Domain
Specificity
Recognizes human VEGFR2.
Applications
  • IHC
  • IHC - Paraffin (1 - 2 µg/ml)
  • IHC - Frozen (1 - 2 µg/ml)
  • Western blot (0.5 - 1 µg/ml)
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
Usage
Suitable for use in Western Blot and Immunohistochemistry. Western Blot: 0.5-1 ug/ml. Immunohistochemistry (paraffin, frozen): 1-2 ug/ml.
Presentation
Lyophilized from 1.2% sodium acetate, 2 mg BSA, 0.01 mg sodium azide
Reconstitution
Reconstitute with 1 ml sterile PBS.
Storage
Lyophilized powder may be stored at -20°C. Stable for 1 year at -20°C. Aliquot to avoid freeze-thaw cycles. Store at -20°C. Reconstituted product is stable for 1 year at -20°C.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
About KDR / VEGFR2 / FLK1
P35968 NM_002253 NP_002244.1

LSBio Ratings

KDR / VEGFR2 / FLK1 Antibody (Extracellular Domain) for IHC, WB/Western LS-C122532 has an LSBio Rating of
Publications (4)

Publications (1)

Reduced Microvascular Density in Omental Biopsies of Children with Chronic Kidney Disease. Burkhardt D, Bartosova M, Schaefer B, Grabe N, Lahrmann B, Nasser H, Freise C, Schneider A, Lingnau A, Degenhardt P, Ranchin B, Sallay P, Cerkauskiene R, Malina M, Ariceta G, Schmitt CP, Querfeld U. PloS one. 2016 November;11:e0166050. (Human)

Customer Reviews (0)


Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at:

Technical.Support@LSBio.com

Requested From: United States
Date Requested: 4/24/2024